Clinical trial
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
NCT00210327 · International Extranodal Lymphoma Study Group (IELSG), Other · Completed
Key facts
| NCT number | NCT00210327 |
|---|---|
| Title | VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy |
| Official title | Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-cell Lymphoma of MALT-type Pretreated With Prior Systemic Therapy Regimen (X05142) |
| Lead sponsor | International Extranodal Lymphoma Study Group (IELSG), Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Mucosa-Associated Lymphoid Tissue |
| Intervention type | Drug |
| Interventions | Bortezomib (drug) |
| Enrollment | 33 |
| Start date | Jul 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Sep 21, 2005 |
| Last update posted | Jul 22, 2009 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: